Regulation of neutrophil superoxide by antichymotrypsin-chymotrypsin complexes.
The ability of neutrophils to generate free radicals is a crucial component of host defense (Babior, B. M. (1978) N. Engl. J. Med. 298, 659-668, 721-725. Neutrophil oxidants, however, can cause significant host tissue destruction (Weiss, S. J. (1989) N. Engl. J. Med. 320, 365-376), and the regulation of free radical production is not well understood. We have previously shown that recombinant antichymotrypsin (rACT), a serine protease inhibitor, inhibits superoxide production in intact neutrophils (Kilpatrick, L., Johnson, J. L., Nickbarg, E. B., Wang, Z., Clifford, T. F., Banach, M., Cooperman, B. S., Douglas, S. D., and Rubin, H. (1991) J. Immunol. 146, 2388-2393). Using a cell-free NADPH oxidase preparation, we now demonstrate that rACT alone has no effect on superoxide production and that antichymotrypsin-chymotrypsin (rACT.CT) complexes are required to inhibit superoxide, suggesting that neutrophil chymotrypsin-like proteases produce conformational changes in ACT, allowing it to become active in regulating superoxide production. Additionally, we have identified NADPH oxidase itself as the target for rACT.CT and have demonstrated that rACT.CT interferes specifically with activation of the NADPH oxidase without changing the Km for NADPH or the rate constant describing the rate-limiting step in activation. These observations suggest an important role for antichymotrypsin in the regulation of NADPH-oxidase activation, which is a prerequisite for neutrophil superoxide production, and predict possible therapeutic uses for rACT in conditions where unregulated neutrophil-free radical production has been implicated in the mechanism of tissue destruction.
Schuster
M G
MG
Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104.
Enriquez
P M
PM
Curran
P
P
Cooperman
B S
BS
Rubin
H
H
D016718:Arachidonic Acid / Q000494:pharmacology; D002918:Chymotrypsin / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D009247:NADH, NADPH Oxidoreductases / Q000097:blood; D009249:NADP / Q000097:blood; D019255:NADPH Oxidases; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D010084:Oxidation-Reduction; D011994:Recombinant Proteins / Q000494:pharmacology; D013481:Superoxides / Q000097:blood*; D000514:alpha 1-Antichymotrypsin / Q000494:pharmacology*
D011994:Recombinant Proteins; D000514:alpha 1-Antichymotrypsin; D013481:Superoxides; D016718:Arachidonic Acid; D009249:NADP; D009247:NADH, NADPH Oxidoreductases; D019255:NADPH Oxidases; D002918:Chymotrypsin